Synthesis of 11,12-dihydro benzo[c]phenanthridines via a Pd-catalyzed unusual construction of isocoumarin ring/FeCl
Animals
Benzene Derivatives
/ chemical synthesis
Catalysis
Cell Line
Chemistry Techniques, Synthetic
Cyclic Nucleotide Phosphodiesterases, Type 4
/ chemistry
Cyclization
Humans
Isocoumarins
/ chemical synthesis
Molecular Docking Simulation
Palladium
/ chemistry
Phenanthridines
/ chemical synthesis
Phosphodiesterase 4 Inhibitors
/ chemical synthesis
Benzo[c]phenanthridine
FeCl(3)
Isocoumarin
PDE4
Pd-catalyst
Journal
Bioorganic chemistry
ISSN: 1090-2120
Titre abrégé: Bioorg Chem
Pays: United States
ID NLM: 1303703
Informations de publication
Date de publication:
04 2020
04 2020
Historique:
received:
27
09
2019
revised:
09
11
2019
accepted:
20
02
2020
pubmed:
7
3
2020
medline:
2
3
2021
entrez:
7
3
2020
Statut:
ppublish
Résumé
In spite of their various pharmacological properties the anti-inflammatory potential of benzo[c]phenanthridines remained underexplored. Thus, for the first time PDE4 inhibitory potential of 11,12-dihydro benzo[c]phenanthridine/benzo[c]phenanthridine was assessed in vitro. Elegant synthesis of these compounds was performed via a multi-step sequence consisting of a Pd-catalyzed unusual construction of 4-allyl isocoumarin ring and FeCl
Identifiants
pubmed: 32143019
pii: S0045-2068(19)31615-3
doi: 10.1016/j.bioorg.2020.103691
pii:
doi:
Substances chimiques
Benzene Derivatives
0
Isocoumarins
0
Phenanthridines
0
Phosphodiesterase 4 Inhibitors
0
Palladium
5TWQ1V240M
Cyclic Nucleotide Phosphodiesterases, Type 4
EC 3.1.4.17
PDE4B protein, human
EC 3.1.4.17
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
103691Informations de copyright
Copyright © 2020 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.